Girentuximab (CAT#: TAB-707)

Datasheet

DESCRIPTION	CATALOG #	SIZE	PRICE
Anti-CAIX/CA9 Recombinant Antibody (Rencarex)	TAB-707	1mg	Please Inquiry

PRODUCT INFORMATION

Product Overview
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.

Applications
Suitable for use in WB, ELISA, IP, FC, FuncS, Neut, IF and most other immunological methods.

Storage
Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Introduction
Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.

Antigen Description
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidney or most other normal tissues. It may be involved in cell proliferation and transformation. This gene was mapped to 17q21.2 by fluorescence in situ hybridization, however, radiation hybrid mapping localized it to 9p13-p12.

Function
carbonate dehydratase activity; lyase activity; metal ion binding; zinc ion binding;

Synonyms
CA9; carbonic anhydrase IX; carbonic anhydrase 9; CAIX; carbonic dehydratase; MN; RCC associated protein G250; pMW1; CA-IX; P54/58N; membrane antigen MN; carbonate dehydratase IX; RCC-associated antigen G250; RCC-associated protein G250; renal cell carcinoma-associated antigen G250;

Related Products

Online Inquiry